All about blinatumomab: the bispecific T cell engager immunotherapy for B cell acute lymphoblastic leukemia

All about blinatumomab: the bispecific T cell engager immunotherapy for B cell acute lymphoblastic leukemia

Introduction: B cell acute lymphoblastic leukemia-lymphoma (B-ALL) accounts for approximately 75% of ALL cases and is observed in children and adults. Recent advances in disease diagnosis, stratification and prognostication have led to a better characterization of different subgroups of ALL. Notwith...

Full description

Bibliographic Details
Main Authors: Reza Mirfakhraie, Bentolhoda Kuhestani Dehaghi, Mahmoud Dehghani Ghorbi, Haniyeh Ghaffari-Nazari, Mozhdeh Mohammadian, Maryam Salimi, Maria Tavakoli Ardakani, Sayeh Parkhideh
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:Hematology, Transfusion and Cell Therapy
Subjects:
Acute lymphoblastic leukemia
Lymphoma
Blinatumomab
Minimal residual disease
Relapsed/refractory
Online Access:http://www.sciencedirect.com/science/article/pii/S2531137923001487

Internet

http://www.sciencedirect.com/science/article/pii/S2531137923001487

Similar Items